Follow the royalty stack down and you reach the lipid. The University of Pennsylvania holds US12576040B2, "Ionizable lipids and methods of manufacture and use thereof" (issued March 17, 2026), among inventors associated with the foundational mRNA-delivery work. The CPC tags — A61K 9/127 (liposome formulations), A61K 47/18/47/28 (carriers), C12N 15/88 (delivery of nucleic acids) — confirm this is delivery IP, the layer that makes an mRNA therapy actually reach cells.
Here is why a delivery grant reshapes a deal teardown. An mRNA medicine is two inventions stacked: the sequence (what you encode) and the delivery vehicle (how you get it in). A company can own its sequence outright and still owe a royalty on the lipid that carries it. When you teardown an mRNA deal and only count the sequence IP, you miss a tier — the delivery license — that can sit upstream of the whole product's economics.
The structure point: upstream delivery IP held by a university is usually licensed broadly, which is both an opportunity and an overhang. Broad licensing means many developers can access the platform; it also means many products may carry the same royalty obligation, and the holder's leverage scales with how indispensable the lipid class proves. For a deals desk, the question is whether a given mRNA program's vehicle reads on this kind of grant — and if so, what that adds to the effective royalty burden.
What the grant does not decide: clinical efficacy, manufacturing yield, or whether a competitor's differently-structured lipid escapes the claims. Ionizable-lipid chemistry is a crowded field with many granted variants; one grant covers its specific chemical space, not the entire concept of LNP delivery. Reading a single lipid patent as control over all mRNA delivery overstates it.
The takeaway for the business reader: when modeling an mRNA deal, do not stop at the sequence. Pull the delivery IP and ask whether the product's lipid reads on upstream grants like this University of Pennsylvania one. The vehicle is often where the quiet royalty lives — and naming the specific grant is how a teardown captures the tier the headline deal value tends to skip.